Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone (Q47279555)

13 January 2018

title

Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone (English)

1 reference

13 January 2018

0 references

Peter J Weiden

1

1 reference

13 January 2018

John W Newcomer

2

1 reference

13 January 2018

Antony D Loebel

3

1 reference

13 January 2018

Ruoyong Yang

4

1 reference

13 January 2018

Harold E Lebovitz

5

1 reference

13 January 2018

language of work or name

English

0 references

publication date

18 July 2007

1 reference

13 January 2018

published in

Neuropsychopharmacology

1 reference

13 January 2018

volume

33

1 reference

13 January 2018

issue

5

1 reference

13 January 2018

page(s)

985-994

1 reference

13 January 2018

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Causes of the excess mortality of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Blood cholesterol screening influence of fasting state on cholesterol results and management decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Physical activity patterns in adults with severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Weight gain and new onset diabetes associated with olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Dietary intake profile of patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Atypical antipsychotics and glucose dysregulation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

The mortality experience of individuals on the Salford Psychiatric Case Register. I. All-cause mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

The unhealthy lifestyle of people with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Body mass index in persons with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Effect of initial ziprasidone dose on length of therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

The metabolic effects of antipsychotic medications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Weight loss in women participating in a randomized trial of low-fat diets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301482

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301482

1 reference

13 January 2018

Dimensions Publication ID

1053484324

0 references

1 reference

13 January 2018